Summary

Acromegaly is caused by an overproduction of growth hormone, and subsequently, insulin-like growth factor-I. ALT1103 is second-generation drug that reduces expression of the growth hormone receptor. In a phase 2 trial, patients with acromegaly who received 400 mg of ALT1103 showed a significant reduction in insulin-like growth factor-I at 14 weeks.